Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice

Mingqiang Ren, Haiyan Qin, Qing Wu, Natasha M. Savage, Tracy I. George, John K. Cowell

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Acute myelogenous leukemia (AML) has an overall poor survival rate and shows considerable molecular heterogeneity in its etiology. In the WHO classification there are >50 cytogenetic subgroups of AML, many showing highly specific chromosome translocations that lead to constitutive activation of individual kinases. In a rare stem cell leukemia/lymphoma syndrome, translocations involving 8p11 lead to constitutive activation of the fibroblast growth factor receptor 1 (FGFR1) kinase. This disorder shows myeloproliferative disease with almost invariable progresses to AML and conventional therapeutic strategies are largely unsuccessful. Because of the rare nature of this syndrome, models that faithfully recapitulate the human disease are needed to evaluate therapeutic strategies. The t(8;13)(p11;q12) chromosome translocation is most common rearrangement seen in this syndrome and creates a ZMYM2-FGFR1 chimeric kinase. To understand more about the molecular etiology of AML induced by this particular rearrangement, we have created a model human CD34+ cells transplanted into immunocompromized mice which develop myeloproliferative disease that progresses to AML with a long (>12 months) latency period. As in humans, these mice show hepatospenomegaly, hypercellular bone marrow and a CD45 + CD34 + CD13+ immunophenotype. Molecular studies demonstrate upregulation of genes such as KLF4 and FLT3 that promote stemness, and overexpression of MYC, which is associated with suppression of myeloid cell differentiation. This murine model, therefore, provides an opportunity to develop therapeutic strategies against the most common subtype within these FGFR1 driven neoplasms and study the molecular etiology in more depth.

Original languageEnglish (US)
Pages (from-to)836-840
Number of pages5
JournalInternational Journal of Cancer
Volume139
Issue number4
DOIs
StatePublished - Aug 15 2016

Fingerprint

Receptor, Fibroblast Growth Factor, Type 1
Acute Myeloid Leukemia
Phosphotransferases
Chromosomes
Myeloproliferative Disorders
Myeloid Cells
Cytogenetics
Cell Differentiation
Lymphoma
Leukemia
Up-Regulation
Stem Cells
Therapeutics
Bone Marrow
Genes
Neoplasms

Keywords

  • 8p11 translocation
  • AML
  • FGFR1
  • mouse model
  • myeloproliferative disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice. / Ren, Mingqiang; Qin, Haiyan; Wu, Qing; Savage, Natasha M.; George, Tracy I.; Cowell, John K.

In: International Journal of Cancer, Vol. 139, No. 4, 15.08.2016, p. 836-840.

Research output: Contribution to journalArticle

Ren, Mingqiang ; Qin, Haiyan ; Wu, Qing ; Savage, Natasha M. ; George, Tracy I. ; Cowell, John K. / Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice. In: International Journal of Cancer. 2016 ; Vol. 139, No. 4. pp. 836-840.
@article{a4056246f119467482623ff5e3e96691,
title = "Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice",
abstract = "Acute myelogenous leukemia (AML) has an overall poor survival rate and shows considerable molecular heterogeneity in its etiology. In the WHO classification there are >50 cytogenetic subgroups of AML, many showing highly specific chromosome translocations that lead to constitutive activation of individual kinases. In a rare stem cell leukemia/lymphoma syndrome, translocations involving 8p11 lead to constitutive activation of the fibroblast growth factor receptor 1 (FGFR1) kinase. This disorder shows myeloproliferative disease with almost invariable progresses to AML and conventional therapeutic strategies are largely unsuccessful. Because of the rare nature of this syndrome, models that faithfully recapitulate the human disease are needed to evaluate therapeutic strategies. The t(8;13)(p11;q12) chromosome translocation is most common rearrangement seen in this syndrome and creates a ZMYM2-FGFR1 chimeric kinase. To understand more about the molecular etiology of AML induced by this particular rearrangement, we have created a model human CD34+ cells transplanted into immunocompromized mice which develop myeloproliferative disease that progresses to AML with a long (>12 months) latency period. As in humans, these mice show hepatospenomegaly, hypercellular bone marrow and a CD45 + CD34 + CD13+ immunophenotype. Molecular studies demonstrate upregulation of genes such as KLF4 and FLT3 that promote stemness, and overexpression of MYC, which is associated with suppression of myeloid cell differentiation. This murine model, therefore, provides an opportunity to develop therapeutic strategies against the most common subtype within these FGFR1 driven neoplasms and study the molecular etiology in more depth.",
keywords = "8p11 translocation, AML, FGFR1, mouse model, myeloproliferative disease",
author = "Mingqiang Ren and Haiyan Qin and Qing Wu and Savage, {Natasha M.} and George, {Tracy I.} and Cowell, {John K.}",
year = "2016",
month = "8",
day = "15",
doi = "10.1002/ijc.30100",
language = "English (US)",
volume = "139",
pages = "836--840",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice

AU - Ren, Mingqiang

AU - Qin, Haiyan

AU - Wu, Qing

AU - Savage, Natasha M.

AU - George, Tracy I.

AU - Cowell, John K.

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Acute myelogenous leukemia (AML) has an overall poor survival rate and shows considerable molecular heterogeneity in its etiology. In the WHO classification there are >50 cytogenetic subgroups of AML, many showing highly specific chromosome translocations that lead to constitutive activation of individual kinases. In a rare stem cell leukemia/lymphoma syndrome, translocations involving 8p11 lead to constitutive activation of the fibroblast growth factor receptor 1 (FGFR1) kinase. This disorder shows myeloproliferative disease with almost invariable progresses to AML and conventional therapeutic strategies are largely unsuccessful. Because of the rare nature of this syndrome, models that faithfully recapitulate the human disease are needed to evaluate therapeutic strategies. The t(8;13)(p11;q12) chromosome translocation is most common rearrangement seen in this syndrome and creates a ZMYM2-FGFR1 chimeric kinase. To understand more about the molecular etiology of AML induced by this particular rearrangement, we have created a model human CD34+ cells transplanted into immunocompromized mice which develop myeloproliferative disease that progresses to AML with a long (>12 months) latency period. As in humans, these mice show hepatospenomegaly, hypercellular bone marrow and a CD45 + CD34 + CD13+ immunophenotype. Molecular studies demonstrate upregulation of genes such as KLF4 and FLT3 that promote stemness, and overexpression of MYC, which is associated with suppression of myeloid cell differentiation. This murine model, therefore, provides an opportunity to develop therapeutic strategies against the most common subtype within these FGFR1 driven neoplasms and study the molecular etiology in more depth.

AB - Acute myelogenous leukemia (AML) has an overall poor survival rate and shows considerable molecular heterogeneity in its etiology. In the WHO classification there are >50 cytogenetic subgroups of AML, many showing highly specific chromosome translocations that lead to constitutive activation of individual kinases. In a rare stem cell leukemia/lymphoma syndrome, translocations involving 8p11 lead to constitutive activation of the fibroblast growth factor receptor 1 (FGFR1) kinase. This disorder shows myeloproliferative disease with almost invariable progresses to AML and conventional therapeutic strategies are largely unsuccessful. Because of the rare nature of this syndrome, models that faithfully recapitulate the human disease are needed to evaluate therapeutic strategies. The t(8;13)(p11;q12) chromosome translocation is most common rearrangement seen in this syndrome and creates a ZMYM2-FGFR1 chimeric kinase. To understand more about the molecular etiology of AML induced by this particular rearrangement, we have created a model human CD34+ cells transplanted into immunocompromized mice which develop myeloproliferative disease that progresses to AML with a long (>12 months) latency period. As in humans, these mice show hepatospenomegaly, hypercellular bone marrow and a CD45 + CD34 + CD13+ immunophenotype. Molecular studies demonstrate upregulation of genes such as KLF4 and FLT3 that promote stemness, and overexpression of MYC, which is associated with suppression of myeloid cell differentiation. This murine model, therefore, provides an opportunity to develop therapeutic strategies against the most common subtype within these FGFR1 driven neoplasms and study the molecular etiology in more depth.

KW - 8p11 translocation

KW - AML

KW - FGFR1

KW - mouse model

KW - myeloproliferative disease

UR - http://www.scopus.com/inward/record.url?scp=84976583791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976583791&partnerID=8YFLogxK

U2 - 10.1002/ijc.30100

DO - 10.1002/ijc.30100

M3 - Article

C2 - 27005999

AN - SCOPUS:84976583791

VL - 139

SP - 836

EP - 840

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -